On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine received an FDA EUA for the same indication in persons ≥16 years old on December 11, 2020.1
CLINICAL STUDY — Issuance of the EUA was based primarily on the results of an observer-blind trial in which 30,420 subjects ≥18 years old were randomized 1:1 to receive the Moderna vaccine or placebo at 0 and 4 weeks. Immunocompromised persons and those with a history of SARSCoV-2 infection were excluded. There were 11 cases of COVID-19 among subjects who...
- FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
- Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
- Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
- Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
- In Brief: An Asenapine Patch (Secuado) for Schizophrenia
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America ...
